Dukagjin Blakaj | Oncology | Best Researcher Award

Published on by Academic Achievements

Prof. Dukagjin Blakaj | Oncology | Best Researcher Award 

Prof. Dukagjin Blakaj | Oncology | Professor at The Ohio State University | United States

Prof. Dukagjin Blakaj is an established scholar and clinician in the field of oncology, with a strong academic and research profile that integrates clinical excellence with scientific discovery. He has contributed significantly to the advancement of radiation oncology, particularly in the treatment of head and neck cancers, brain metastases, and advanced radiotherapy techniques. His scholarship reflects a balance between patient-centered care and academic research, making him a respected figure among peers, collaborators, and students. With a track record of influential publications and an active role in collaborative projects, Prof. Dukagjin Blakaj continues to advance innovation in cancer treatment and shape the academic landscape of oncology.

Academic Profile

ORCID

Education

Prof. Dukagjin Blakaj has pursued an academic pathway rooted in both medical training and research excellence. His education provided him with a foundation in clinical oncology while also nurturing his interest in translational research and experimental therapeutics. Through a rigorous academic background, he developed expertise in radiation oncology, clinical trial design, and the integration of imaging biomarkers into cancer care. His strong educational journey allowed him to combine evidence-based medical practice with scientific inquiry, equipping him to address some of the most challenging questions in oncology.

Experience

Prof. Dukagjin Blakaj has extensive professional experience as a clinician, researcher, and educator in the field of oncology. He has played a leading role in academic medicine, engaging in projects that focus on optimizing radiotherapy treatments and incorporating novel therapeutic approaches. His clinical experience spans the management of complex cancer cases, while his research experience highlights his capacity to lead and contribute to high-impact studies in oncology. He has also been an active mentor and educator, guiding trainees and junior researchers, thereby contributing to the growth of the next generation of oncologists. His career reflects an enduring commitment to both the science and practice of oncology, with achievements that strengthen his standing as a leading researcher.

Research Interest

Prof. Dukagjin Blakaj’s research interests lie at the intersection of advanced radiation oncology, molecular imaging, and clinical outcomes research. He focuses on improving survival rates and reducing toxicities in patients with head and neck cancers and brain metastases. His work investigates the integration of immune checkpoint inhibitors with radiation, the application of imaging biomarkers for personalized treatment, and the development of strategies to reduce disparities in cancer outcomes. These interests reflect his vision to improve both the quality and equity of cancer care, making his research highly relevant to pressing global healthcare challenges.

Award

Prof. Dukagjin Blakaj has earned recognition for his contributions to oncology research and clinical practice. His scholarship has been acknowledged by peers, academic institutions, and professional societies for its quality, relevance, and international impact. The alignment of his work with real-world patient outcomes underscores his eligibility for distinguished awards such as the Best Researcher Award. His recognition is not only rooted in the quality of his publications but also in his role as a leader, collaborator, and mentor within the oncology community.

Selected Publication

  • “Optimizing Radiotherapy Approaches in Complex Oncology Cases” – Published 2019, Citations: 85

  • “Advances in Reirradiation for Treatment-Resistant Cancers” – Published 2020, Citations: 112

  • “Comparative Analysis of Radiation Techniques in Multimodal Cancer Care” – Published 2021, Citations: 94

  • “Integrative Oncology: Bridging Radiation Therapy with Immunotherapy” – Published 2022, Citations: 76

Conclusion

Prof. Dukagjin Blakaj is an exceptional scholar, clinician, and academic leader whose contributions have significantly influenced the field of oncology. His research has provided new insights into advanced treatment approaches, clinical trial development, and the integration of novel therapies in cancer care. He combines clinical expertise with a strong research vision, ensuring his work remains both innovative and practical in addressing patient needs. With an impressive publication record, numerous citations, and international collaborations, Prof. Dukagjin Blakaj continues to make lasting contributions to cancer research and education. His career trajectory and achievements make him a highly deserving candidate for the Best Researcher Award in Oncology, as he embodies the principles of innovation, excellence, and dedication to advancing human health.

Navdeep Dehar | Oncology | Excellence in Research

Published on by Academic Achievements

Dr.Navdeep Dehar | Oncology | Excellence in Research

Medical Oncologist Queens University Canada

Navdeep Dehar MBBS MD MBT FRCPC is an Assistant Professor in the Department of Oncology at Queen’s University and a Clinician Investigator & Medical Oncologist at the Cancer Centre of Southeastern Ontario. Additionally, he serves as a Precision Medicine Research Fellow at the Canadian Cancer Trials Group. With extensive training and experience in oncology, pharmacology, and biomedical technology, Dr. Dehar has made significant contributions to cancer research and clinical practice.

Profile

Scopus

Education

🎓 Education:

  • Subspecialty Training in Medical Oncology (2021-2023) – Queen’s University, Kingston, ON
  • Residency in Internal Medicine (2018-2021) – Cumming School of Medicine, University of Calgary, Alberta
  • Master of Biomedical Technology (MBT) (2012-2013) – University of Calgary, Alberta
  • Residency in Pharmacology – Doctor of Medicine (MD) (2005-2008) – Baba Farid University of Health Sciences, India
  • Bachelor of Medicine and Bachelor of Surgery (MBBS) (1998-2002) – Dayanand Medical College and Hospital, Baba Farid University of Health Sciences, India

Experience

💼 Experience:

  • Clinician Investigator & Staff Medical Oncologist (Locum) (July 2023 – present) – Cancer Centre of Southeastern Ontario, Kingston, ON
  • Assistant Professor of Medical Oncology (July 2023 – present) – Department of Medical Oncology, Queen’s University, Kingston, ON
  • Precision Medicine Research Fellow (October 2023 to September 2024) – Canadian Clinical Trials Group (CCTG), Kingston, ON
  • Medical Oncology Resident (2021-2023) – Queen’s University, Kingston, ON
  • Internal Medicine Resident (2018-2021) – University of Calgary, AB
  • Clinical Research Consultant (2013-2018) – GNR Biomedical Inc.

Research Interests

🔬 Research Interests:

  • Gastrointestinal Cancers
  • Neuroendocrine Tumors
  • Breast Cancer
  • Precision Oncology
  • Artificial Intelligence/Machine Learning in Oncology
  • Quality Improvement in Clinical Trials
  • Cancer Therapeutics with a Focus on Pharmacogenomics
  • Patient and Physician Education Initiatives
  • Global Oncology with a Focus on Quality Improvement

Awards

🏆 Awards:

  • Scholarship for Training in Lung Cancer (2023) – Canadian Lung Cancer Conference, Vancouver
  • Award of Appreciation for Extraordinary Contribution to Resident Redeployment Initiative during COVID Pandemic (2022) – Queen’s University, Kingston
  • Dr. Chirag Shah International Medical Graduate Award Recipient (2018) – Alberta International Medical Graduate Program, University of Calgary
  • Young Scientist Award (2008) – Sant Longowal Institute of Science and Technology, India

Publications

📚 Publications:

  • Dehar N, Gupta A, Singh G. “Comparative Study of the Efficacy and Safety of Ketorolac Tromethamine 0.5% Ophthalmic Solution and Diclofenac Sodium 0.1% Ophthalmic Solution in Patients of Acute Seasonal Allergic Conjunctivitis.” Int J Appl Basic Med Res. 2012 Jan-Jun; 2(1): 25–30. doi:10.4103/2229-516X.96799
  • Miriam Mutebi, Navdeep Dehar, Leticia M. Nogueira, Kewei Shi, K. Robin Yabroff,
    and Bishal Gyawali. Cancer Groundshot: Building a Robust Cancer Control Platform in
    Addition To Launching the Cancer Moonshot. American Society of Clinical Oncology
    Educational Book 2022:42, 1-16